A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: An endorsement with some caveats for real-life application

Nephrology Dialysis Transplantation

Volumn 29, Issue 3, 2014, Pages 490-496

  Verbeke, Francis ^a   Lindley, Elisabeth ^b   Van Bortel, Luc ^c   Vanholder, Raymond ^a   London, Gérard ^d   Cochat, Pierre ^e   Wiecek, Andrzej ^f   Fouque, Denis ^g,h   Van Biesen, Wim ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c GHENT UNIVERSITY   (Belgium)

^d Hopital FH Manhes   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h UNIVERSITÉ LYON 1   (France)

Author keywords

Chronic kidney disease; European Renal Best Practice; Guideline; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE;

ADD ON THERAPY; ALBUMINURIA; ARTERIAL STIFFNESS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG CHOICE; GOOD CLINICAL PRACTICE; HUMAN; HYPERTENSION; HYPERVOLEMIA; KIDNEY DENERVATION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; METABOLIC DISORDER; PERSONALIZED MEDICINE; POSITIONAL DIZZINESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SODIUM RESTRICTION; UNSPECIFIED SIDE EFFECT; AGED; BLOOD PRESSURE; DISEASE MANAGEMENT; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; TOTAL QUALITY MANAGEMENT;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MANAGEMENT; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITY IMPROVEMENT; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84895733247     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft321     Document Type: Review

References (27)

1. KDIGO Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2012; 2(Suppl.): 337-414
2. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004; 141: 614-627
3. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645
4. National Clinical Guideline Center. The clinical management of primary hypertension in adults. Commissioned by the National Institute of Health and Clinical Excellence. Hypertension Clinical Guideline 127 2011 (NICE CG 127), 2011. http://publications.nice.org.uk/hypertension-cg127/guidance#diagnosing- hypertension-2
5. van Popele NM, Bos WJ, de Beer NAM et al. Arterial stiffness as underlying mechanism of disagreement between an oscillometric blood pressure monitor and a sphygmomanometer. Hypertension 2000; 36: 484-488
6. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
7. Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213
8. Remuzzi G, Ruggenenti P, Perna A et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15: 3117-3125
9. Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140
10. Ahmed AK, Kamath NS, El KM et al. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010; 25: 3977-3982
11. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54: 889-896
12. Bakris GL,Weir MR, SecicM et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65: 1991-2002
13. Griffin KA, Picken MM, Bakris GL et al. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999; 55: 1849-1860
14. Neutel JM, Schnaper H, Cheung DG et al. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J 1990; 120: 166-171
15. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225
16. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl 2004; 1: 17-32
17. Neumann J, Ligtenberg G, Klein II et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65: 1568-1576
18. Bleyer AJ, Hartman J, Brannon PC et al. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006; 69: 2268-2273
19. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4-9
20. Major outcomes in high-risk hypertensive patients randomized to angiotensin- converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
21. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898
22. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041
23. Ambrosioni E, Safar M, Degaute JP et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J Hypertens 1998; 16: 1677-1684
24. Krum H, Skiba M, Gilbert RE. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. Diabet Med 2003; 20: 708-712
25. Verbeke F, Marechal C, Van LS et al. Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension 2011; 58: 833-838
26. Wuhl E, Trivelli A, Picca S et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361: 1639-1650
27. Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol 2009; 54: 1827-1834